In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
about
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debateIntra-tumor heterogeneity of cancer cells and its implications for cancer treatmentTumour Heterogeneity: The Key Advantages of Single-Cell AnalysisProgress in the clinical detection of heterogeneity in breast cancerProceedings of the third international molecular pathological epidemiology (MPE) meeting.Translating neoadjuvant therapy into survival benefits: one size does not fit all.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeThe Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".Building a lineage from single cells: genetic techniques for cell lineage tracking.DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancerCancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.AKT signaling in ERBB2-amplified breast cancer.Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolismA Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidA Microchip for Integrated Single-Cell Gene Expression Profiling and Genotoxicity Detection.Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations.Catalog of genetic progression of human cancers: breast cancer.Progression inference for somatic mutations in cancer.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Genome evolution in ductal carcinoma in situ: invasion of the clones.The Cellular Origin and Evolution of Breast Cancer.Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers.Recent progress in single-cell cancer genomics.Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.The Secret Life of RNA: Lessons from Emerging Methodologies.Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution.Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures.Diversity index as a novel prognostic factor in breast cancer.Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer.Platform for Quantitative Evaluation of Spatial Intratumoral Heterogeneity in Multiplexed Fluorescence Images.The significance of intertumor and intratumor heterogeneity in liver cancer.Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells.Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860
Q24273274-39CC05EC-9A21-4306-B4FD-9476171BAFE1Q26783055-2AEDB41F-0CBA-4899-8CC6-ED4819F76E26Q28066914-54069496-9B36-4961-A3CE-1EE25D46F861Q28079224-8CD06E55-3701-4833-90F7-17050DC2A68BQ30238962-FAB0A0CE-8FBB-4070-BA5F-EA693D004EA4Q30251738-8636C9E8-91A4-4475-8E77-F3333B19E3B8Q33823065-01EFEB26-2DB9-4AB0-9BA9-C58FFCCC80C4Q33913152-D4D1E239-9D55-4DA9-9C23-59CCC3146BF8Q36233893-D2F9A448-3B2D-4AB6-B667-35DA98C14DC9Q36256840-FB7194E3-D308-48F1-8D72-DC077211399CQ36540420-4B8C8A73-8FD6-4930-8551-2CF2DFD92E04Q36544839-7B018E1C-1FCC-4BB4-83D0-44B87E32CECAQ36563578-95103ECD-5890-43D0-A231-054F375D0CAEQ36774477-51EC2092-0D26-415E-A52C-03D7B3BCA9B6Q36891604-8340129D-7F90-4CD3-8EAF-8D2ED93792DCQ37029832-A84A4CF7-2337-427A-A9BE-75C6FD370CD5Q37168845-6A8CB41E-9D98-4E24-8196-73F4B9BF4C68Q37289122-32042A0E-39A2-496D-A071-8AC16E8BBE91Q37745803-20572FED-6B87-4030-81E4-E31B6EBB9DF3Q38733590-8BB491C8-404D-42BC-8941-0A4A8FA31BD8Q38764251-66A1FCE2-8B63-4D57-8497-E202A41F6806Q38793244-1182AD99-5150-4A33-8102-5F7BBF50CDF0Q38888022-DC7B2BBC-E97F-42E7-8773-9F3572CCD463Q39012815-C2CF8053-7DA7-4AD1-BE19-051FBB32A3CEQ39071403-FA14E584-5727-4136-97B8-1C9B3DCE7DD2Q39085383-31529FA5-1472-4FF0-BB1E-C29DE06FDB2DQ39105559-96F27415-EDB6-44BC-A0CA-D0B75196330DQ39176607-1D79C4B1-85B8-4FC1-9C0D-1628723A0061Q45848384-8E0E083E-B58F-49B6-8DCA-203DC4AA643AQ46262964-BF2ACB21-CA53-40DF-81C4-85DD9F8F6970Q47137439-6A7269EB-D778-4A1D-8B1F-49520EBE36D7Q47149090-B2EB94B7-FBF0-44A9-A58F-86DE8404B719Q47162348-29352D93-7E58-40C6-8E2F-7D381D57C28AQ47361762-EB47B369-2CC1-402C-B887-300C8CC1C5C2Q47566062-47239E12-FA99-49CE-B7CC-52D975EDE829Q47750195-12E7781E-1F07-45C0-8772-5D9391589B6DQ49179749-D2CD8B4D-802E-4DEE-8E07-38BF7155123BQ54957080-371DF5B1-FDBD-4DD1-83B2-71339E9D950DQ55241465-26AA229E-ACF8-4D9E-898A-C7A92934EE4DQ58801931-130F303C-CF03-4367-B222-341FB4F305D4
P2860
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@ast
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@en
type
label
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@ast
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@en
prefLabel
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@ast
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
In situ single-cell analysis i ...... n HER2-positive breast cancer.
@en
P2093
Carlos L Arteaga
Cloud Paweletz
Franziska Michor
Kornelia Polyak
Michalina Janiszewska
Rita A Sakr
Sarat Chandarlapaty
Tari A King
Vanessa Almendro
P2860
P2888
P304
P356
10.1038/NG.3391
P407
P577
2015-08-24T00:00:00Z